Who bought Amylin Pharmaceuticals?

Who bought Amylin Pharmaceuticals?

Bristol-Myers Squibb
AstraZeneca and Bristol-Myers Squibb today announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb.

What happened Amylin Pharmaceuticals?

The company was engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases….Amylin Pharmaceuticals.

Type Subsidiary
Founded 1987
Defunct 2012
Fate Acquired by Bristol-Myers Squibb and AstraZeneca
Headquarters San Diego, California, United States

When did BMS acquire Amylin?

August 9, 2012
The acquisition of Amylin by Bristol-Myers Squibb was completed August 9, 2012.

Where is Amylin Pharmaceuticals located?

San Diego
Amylin Pharmaceuticals is a biopharmaceutical firm located in San Diego, California, with over 1,000 employees in the US. Amylin has developed and gained approval for two first-in-class medicines for the treatment of type I and type II diabetes, Symlin (pramlintide acetate) injection and Byetta (exenatide) injection.

Where is amylin secreted?

pancreatic beta cells
Amylin is a 37-amino-acid peptide that is co-secreted with insulin from the pancreatic beta cells. Therefore, unlike true enteroendocrine peptides, amylin is secreted primarily in response to postabsorptive stimulation of pancreatic beta cells by glucose.

What are amylin analogs?

Amylin analogs are used in the treatment of diabetes. They are stable synthetic compounds, which are administered subcutaneously before meals, and work similarly to the physiological amylin. Amylin is a 37 amino acid polypeptide hormone that is secreted with insulin from the beta cells in the pancreas.

Who makes symlin?

Pramlintide (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca)….Pramlintide.

Clinical data
Bioavailability 30 to 40%
Protein binding ~60%
Metabolism Renal
Elimination half-life ~48 minutes

Related Posts